Multi-Phasic CECT Peritumoral Radiomics Predict Treatment Response to Bevacizumab-Based Chemotherapy in RAS-Mutated Colorectal Liver Metastases.

This study aims to investigate the predictive value of pre-treatment multi-phasic contrast-enhanced computed tomography (CECT) radiomic features for treatment resistance in patients with rat sarcoma virus (RAS)-mutated colorectal liver metastases (CRLMs) receiving bevacizumab-based chemotherapy. Seventy-three samples with RAS-mutated CRLMs receiving bevacizumab-combined chemotherapy regimens were evaluated. Radiomic features were extracted from arterial phase (AP), portal venous phase (PVP), AP-PVP subtraction image, and Delta phase (DeltaP, calculated as AP-to-PVP ratio) images. Three groups of radiomics features were extracted for each phase, including peritumor, core tumor, and whole-tumor regions. For each of the four phases, a two-sided independent Mann-Whitney U test with the Bonferroni correction and K-means clustering was applied to the remnant features for each phase. Subsequently, the Least Absolute Shrinkage and Selection Operator (LASSO) algorithm was then applied for further feature selection. Six machine learning algorithms were then used for model development and validated on the independent testing cohort. Results showed peritumoral radiomic features and features derived from Laplacian of Gaussian (LoG) filtered images were dominant in all the compared machine learning algorithms; NB models yielded the best-performing prediction (Avg. training AUC: 0.731, Avg. testing AUC: 0.717) when combining all features from different phases of CECT images. This study demonstrates that peritumoral radiomic features and LoG-filtered pre-treatment multi-phasic CECT images were more predictive of treatment response to bevacizumab-based chemotherapy in RAS-mutated CRLMs compared to core tumor features.